Argenx SE

Argenx SE’s new CEO signals a bold shift toward next‑gen antibody therapies, backed by a “Buy” rating and a revised target price, driving investor confidence and global expansion plans.

Argenx SE’s split analyst ratings reflect its strong revenue base but rising R&D costs and regulatory hurdles, with pipeline prospects like TNB‑585 and BMS‑986192 driving debate.

Argenx’s antibody‑engineering expertise fuels a diversified pipeline—autoimmune and oncology—while AI‑driven design cuts lead‑generation time, positioning the Dutch biotech for 18% revenue growth.

Argenx stops its Phase‑3 efgartigimod trial for thyroid eye disease, yet remains a bullish investment with FDA‑approved therapies, robust pipeline, and steady analyst support.

Argenx’s phase‑III TED trial halt sparks a brief stock dip, yet investors stay bullish on its diversified pipeline, strong cash, and strategic partnerships, showing resilience amid challenges.

Argenx shares rise on strong oncology data and a diversified bispecific pipeline, highlighting AMG 557’s melanoma success and future regulatory prospects.

Argenx SE, a European biotechnology firm, has reported a 95.3% year-over-year increase in revenue, driven by strong sales of its flagship antibody therapy, VYVGART, which has shown promising efficacy in treating seropositive generalized myasthenia g…

Argenx SE, a Berlin-based biotechnology firm, has achieved remarkable growth and a market capitalization of over €41 billion, driven by its focus on antibody-based therapies for autoimmune and oncology indications, but faces regulatory, competitiv…

Argenx SE, a European biotechnology firm, has seen a significant increase in its stock value following the release of positive clinical data for its antibody-based therapeutic pipeline, with investors anticipating successful late-stage trials and po…

Argenx SE has demonstrated remarkable growth and financial performance, driven by its focus on antibody-based therapies for severe autoimmune diseases and oncology, and its ability to navigate complex reimbursement environments and operational chall…